ABCB1 and cancer: The failure of clinical trials on MDR1 inhibitors such as tariquidar (Pusztai et al., 2005) and zosuquidar (Cripe et al., 2010) also suggests that, in order to block the potential drug efflux of cancer cell entirely, we need to consider the specificity of as much transporters as possible in the design phase of new drugs.